Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Q Holdings

Request full access

Advanced cellular therapeutics for incurable CNS diseases, focusing on glial cell-based treatments

Salt Lake City, United StatesFounded 2004Biotech & Life Sciences

About Q Holdings

Q Therapeutics is pioneering the development of human cell-based therapies aimed at treating debilitating and currently incurable diseases of the central nervous system (CNS), including the brain and spinal cord. The company’s innovative approach centers on glial cells, which are non-neuronal cells in the CNS essential for supporting, repairing, and maintaining normal neuron function and health. Q Therapeutics is currently advancing its therapeutic pipeline with an FDA-approved IND application to proceed with a Phase 1/2a clinical trial for patients with Transverse Myelitis (TM), a severe inflammation of the spinal cord that affects approximately 40,000 people in the United States. TM, similar to Multiple Sclerosis, destroys the myelin sheath surrounding nerve fibers in the spinal cord, leading to compromised muscle control and sensation. Q Therapeutics operates in the biopharmaceutical market, targeting healthcare providers and patients suffering from CNS diseases. The company’s business model involves conducting clinical trials to validate the efficacy and safety of its therapies, followed by seeking regulatory approvals and commercializing the treatments. Revenue generation is expected through the sale of approved therapies and potential partnerships or licensing agreements with larger pharmaceutical companies.

Source: Dealroom company data

Q Holdings in the Salt Lake City ecosystem

Live from Dealroom

The Q Holdings office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Signal Peak Ventures
  • vSpring Capital
  • Salt Lake Life Science Angels (SLLSA)
  • University of Utah Endowment
  • EPIC Ventures
  • Toucan Capital
  • Q management
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Q Holdings on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Q Holdings on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.